Protalix BioTherapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $-6.0M | $39.0M |
| FY2022 | — | $-10.6M | $17.1M |
| FY2023 | — | $33.6M | $23.6M |
| FY2024 | — | $43.2M | $19.8M |
| FY2025 | — | $48.2M | $14.7M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $-6.0M | $39.0M |
| FY2022 | — | $-10.6M | $17.1M |
| FY2023 | — | $33.6M | $23.6M |
| FY2024 | — | $43.2M | $19.8M |
| FY2025 | — | $48.2M | $14.7M |